Medtronic’s Renal Denervation System Fails to Sway FDA Advisory Panel
The US FDA advisory panel did not endorse the use of the Symplicity Spyral renal denervation device for patients with uncontrolled hypertension, due to concerns over its effectiveness and risk-benefit profile.